Please login to the form below

Not currently logged in
Email:
Password:

MS symptom drug approved in US

The US FDA has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis

The US Food and Drug Administration (FDA) has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). Ampyra is the first therapy to be approved for this use.

The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics.

Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics on the approval of Ampyra, which will bring a very important and much needed therapy to the market for MS sufferers."

Data from clinical trials shows that patients treated with Ampyra had faster walking speeds than those receiving a placebo. MS is a chronic disease affecting the central nervous system, often with disability affects. It is estimated to affect around 400,000 people in the US and 2.5 million people worldwide.

When given in doses higher than the recommended 10mg twice daily, Ampyra can cause seizures. Other reported side effects include insomnia, nausea, weakness and balance disorder.

25th January 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics